A Postmarket Registry of the BioMatrix and BioMatrix Flex Drug Eluting Stents.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Dec 2015
At a glance
- Drugs Umirolimus (Primary)
- Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms eBMX-PMR
- Sponsors Biosensors International Group
- 06 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2016 to 1 Apr 2015.
- 21 May 2013 New registry data were presented at EuroPCR 2013, according to a Biosensors International Group.
- 02 Jan 2013 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.